Some thoughts on the $IPIX 8k and the notes from a couple
Some thoughts on the $IPIX 8k and the notes from a couple of posters who attended the $IPIX shareholder meeting:
- There were 150M YES vs 14M NO votes on the authorized share increase. That represents more than a 10 to 1 ratio. This validates that a very large majority of $IPIX shares are STRONGLY held by investors that believe in $IPIX science and trust Leo to continue to wisely manage financial resources of stock issuance required for $IPIX science advancement.
- It is and will be very telling if $IPIX share price continues to be compressed. With 150M+ shares strongly held, where will the sellers come from? Does anyone believe that shareholders that voted YES will sell their shares for pennies or is it more likely that they are hanging on longer term for dollars? Typically you need to have both a seller and a buyer to make a transaction. I believe we will see a lot of “volume” without a lot of sellers. How is that logically possible?……..hmm UNLESS they are not real transactions! There will likely be more counterfeit shares with bogus transactions as the NSS/NR/criminals keep digging themselves into a deeper hole. I am also guessing that some of the investors that make up the 150M share count that are STRONG & LONG will take advantage of some additional bargain hunting courtesy of the criminals.
- B-OM phase 3 guidelines are for 300 active drug recipients. + 150 placebo which is set up to be a very favorable trial for streamlined advancement. It only takes 1 of the several interested parties to finalize a deal. Note that $IPIX is not jumping into any trials without first securing non-dilutive financing to fund that particular trial. A B-OM partnership could be inked without warning at which time a relatively short B-OM phase3 trial will quickly commence.
- My favorite quote from a shareholder note from Dr. Bertolino regarding B-IBD pill was “BP wants to see a 2a. BP told them that if they can show them a successful 2a, they will be “knocking their door down“. If that quote doesn’t get you extremely excited about $IPIX, you probably shouldn’t be invested in biotech IMO. Dr. Bertolino also was quoted: “Dr. B spoke up and said, “I’m still here after 3 years, and if I didn’t believe, I wouldn’t be here anymore.”
- Another great quote: “Leo said that he will provide more clarity in the coming weeks. “A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.” I personally believe Leo is more than just a fiscally prudent CEO. I believe he will execute a well thought out plan and that no one not named Leo or Arthur will be able to predict the exact WHAT or the exact WHEN. Long term investors will want to have maximum exposure as this plan unfolds and the science progresses.
- IMO the Alfasigma deal was the foundation for the Brilacidin franchise. Having a partner fund trials to advance and further validate the science is huge. I personally believe this was a great milestone regardless of whatever upfront cash $IPIX ended up with in the deal. The Right of First Refusal is financially a good floor for future IBD instance negotiation but this contractual feature strongly favors $IPIX to maximize Brilacidin IBD monetization.
- Per the POS AM financial filing it appears that Outstanding Share count will rise from 205,620,200 up to approximately 262,535,967. I am personally more than OK with a share count under 300M shares as IPIX enters multiple instances in mult-billion dollar markets. B-OM phase 3 costs will be paid for by a B-OM future partner. B-IBD UP/UPS is being paid for by Alfasigma. B-IBD Colitis will be paid for by whatever BP partner ‘knocks the door down” to grab a big chunk of a $48B market. We may see some type of Kevetrin partnership down the road but in the meantime IPIX will use some resources to advance Kevetrin pill form which if successful will make $IPIX shareholders very wealthy IMO.
Summary:
$IPIX continues to advance their science with frugal management of resources. The Alfasigma deal is the foundation for the Brilacidin franchise. The announced B-IBD pill development with BDD is a huge strategic initiative that positions IPIX in an extremely lucrative IBD colitis market. B-OM is a phase 3 ready instance with multiple parties engaged in partnership discussions with a clearly defined and detailed roadmap paved in cooperation with the FDA. $IPIX is positioned in the EU for trial advancement and eventual distribution.
$IPIX short term share price will continue to be artificially compressed as the criminals have no good option other than to continue to pump out additional counterfeit shares. The NSS crews and SMB bashers are out in full force. The problem for them though is that a vast majority of $IPIX shareholders are Real Longs who are holding and in many cases buying more shares to increase their position and to lower their cost basis. As $IPIX continues to advance the science and as Leo executes strategies and achieves milestones, there will be a pendulum swing in the control of $IPIX share price. The criminals at some point will be forced to try to do a controlled take up. They may or may not be able to control their targeted prices in hopes of shorting them back down. If the 150M share base of LONG & STRONG are right about Leo’s ability to execute and new investors flood into $IPIX stock, then we will be looking at an entirely different situation as far as who is in control and who gets crushed.
21
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Enjay's Bold Move into New Territory Here's a headline that doesn’t just flutter past like yesterday's news. Enjay Converters Ltd, straight from Cobourg, Ontario, has clinched a deal that looks like it might just shake things up a bit on the food packaging scene. They’ve bagged New Method Packaging LLC, another big player, but this time from the heartland of...
Continue Reading
Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...
Continue Reading
The Perks of Specialist Knowledge Ever get the feeling your local auto shop doesn't always cut it when your sleek BMW or classy Mercedes needs a tweak? You're not alone. Specifically, for those driving around Alpharetta, European vehicles demand not just routine check-ups but specialist hands. Much like how you wouldn't hand your luxury timepiece to the shop down the...
Continue Reading
Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...
Continue Reading
Betting Big on Small Business If you've ever run a small business, you know it can feel like a hamster wheel—more customers usually mean more headaches. But here comes Worker.ai, stepping onto the scene with big promises and a fancy new acquisition. They've scooped up DeltaGen—a mover in real-time AI tech—and launched a platform to hand these overworked owners a...
Continue Reading
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...
Continue Reading
Leadership Change at Mayo Clinic: A Turning Point The Mayo Clinic, a titan in healthcare lands, is on the cusp of a major leadership switch-up. As the trustees hand the reins to Dr. Matthew R. Callstrom, they're banking on a rich blend of experience and visionary thinking to steer their ship. We're looking at what this change might spell for Mayo's storied mission. Who is...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Top 5 Most Recently Viewed Articles
Welcome to the World of Jolly Rancher Freeze Dried Candy Prepare your senses for an exhilarating journey with Jolly Rancher Freeze Dried candy. Imagine the familiar fruity flavors you adore, reimagined to deliver a light, crunchy sensation that’s simply unforgettable. A New Era in Candy Snack enthusiasts, get ready as your beloved candy aisle undergoes a delightful...
Continue Reading
Insights into the Class Action Against New Fortress Energy Recently, New Fortress Energy Inc. has become the focus of a securities class action lawsuit. Investors need to stay updated on their rights and what this legal action means for them. The lawsuit addresses several misrepresentations made by the company's leaders that are now being revealed. Breaking Down the...
Continue Reading
United Food Group Introduces Protein-Based Meal Solutions United Food Group, Inc., a food manufacturer based in Elgin, is excited to unveil a new line of convenient, protein-rich meals and drinks specifically designed to cater to the needs of college students. These innovative meals come in single-serve pouches that are both easy to prepare and enjoyable, allowing...
Continue Reading
Milestone Achieved with SmartCert Technology GlobalVetLink (GVL), a leader in digital compliance solutions for animal health, recently celebrated a remarkable achievement. In a mere six months since its launch, the SmartCert Technology has successfully validated over 25,000 animal health certificates. This significant milestone emphasizes the increasing need for effective...
Continue Reading
Municipality Finance Secures EUR 50 Million in New Tranche In a notable financial move, Municipality Finance Plc has successfully issued a new tranche of EUR 50 million under its Medium Term Note (MTN) programme. This issuance is part of the company’s ongoing efforts to support sustainable projects and municipal financing. The new tranche, set to be issued on 5 May,...
Continue Reading